{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000585","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.040854+00:00","generated_at":"2026-05-23T19:31:53.975921+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright","bullets":["ATM agreement for up to $2,641,881 of common stock at market prices.","H.C. Wainwright receives 3.0% cash commission on gross proceeds.","Proceeds will be used for working capital and general corporate purposes.","Shares offered under existing effective S-3 shelf registration.","No obligation to sell; company may suspend or terminate at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000585","json":"https://secwatch.observer/filing/0001753926-25-000585.json","markdown":"https://secwatch.observer/filing/0001753926-25-000585.md","text":"https://secwatch.observer/filing/0001753926-25-000585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000585/0001753926-25-000585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000585/g084763_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:31:53.975921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}